This website uses cookies. By clicking Accept, you consent to the use of cookies. Click Here to learn more about how we use cookies.
Accept
Reject
Help

Upcoming Webinars

cancel
Turn on suggestions
Auto-suggest helps you quickly narrow down your search results by suggesting possible matches as you type.
Showing results for 
Search instead for 
Did you mean: 

Upcoming Webinars
Engineering Polymers that Prevent Rejection of Gene Therapy and 3-D Printed Implants
Thursday, April 13, 2023
Register
3-D printing could be transformative in healthcare by empowering clinicians to quickly create high-quality and affordable custom medical implants, but we need more resins that are biocompatible and can be safely destroyed and absorbed into the body after use. Gene therapies aim to attack disease at the source by inhibiting or correcting the production of problematic proteins BEFORE they have a chance to replicate and require traditional drugs. However, like the resins in additive manufacturing, there are challenges to the body tolerating this new technology, for example rapid renal clearance, inefficient delivery to non-liver organs, and immunogenicity/toxicity.   Polymer scientists are working to develop new technologies to augment and support game-changing treatments like gene therapy and 3-D printed implants so that our bodies can safely tolerate their effects leading to wider use and better outcomes. In this extended webinar from the ACS Division of Polymer Chemistry, Matthew L. Becker of Duke University will outline strategies for synthesizing highly functional oligomeric resins that can be photochemically printed into a variety of structures possessing unique mechanical, chemical and degradation properties, including a number of pre-clinical applications. Then, Ke Zhang of Northeastern University will share how his lab is developing a safe and efficient oligonucleotide delivery technology that addresses non-liver organs, reduces cost, and minimizes off-target effects for gene therapy.   This ACS Webinar is moderated by C. Adrian Figg of Virginia Tech and is co-produced with the ACS Division of Polymer Chemistry.
2023-04-13-stock-600-400px-acsnetwork.jpg
Labels (1)
Labels
Accelerating the Design of Asymmetric Catalysts with a Digital Chemistry Platform
Tuesday, April 18, 2023
Register
Asymmetric catalysis has become an integral part of the science-driven technological revolution in the second half of the 21st century, leading to decreased energy demands, sustainable chemical processes and the realization of “impossible” transformations. Asymmetric catalysis based on chiral transition-metal complexes plays an important role in the synthesis of single-enantiomer drugs, perfumes and agrochemicals. The importance of the field is recognized by two Nobel Prize Awards in 2001 (transition-metal catalysis) and 2021 (organocatalysis).    Asymmetric catalysts are traditionally designed by experimental trial-and-error methods, which are resource-, time- and labor-consuming, and thus extremely expensive. Digital methods offer the opportunity to expedite catalyst design. Until recently, computational chemistry, typically quantum chemical studies, indirectly contributed to asymmetric catalyst design by providing rationalization for the mechanism of generation of chirality. With the development of more advanced methods, algorithms and an included layer of automation, computational catalysis is now providing the possibility for direct asymmetric catalyst design.    In this webinar, we will demonstrate how Schrödinger’s advanced digital chemistry platform can be used to accelerate the direct design and discovery of asymmetric catalysts.     Key Learning Objectives: Learn how to design an asymmetric catalyst with computational chemistry Learn how automated high-throughput simulation workflows enable rapid asymmetric catalyst design Understand the intersection of physics-based and machine learning techniques in asymmetric catalyst design Who Should Attend: Synthetic Chemists Materials Scientists Chemical Engineers Digitization Managers R&D Scientists Designing Novel Catalysts Brought to you by: Speakers: Pavel A. Dub Senior Principal Scientist and Product Manager, Schrödinger Melissa O'Meara Forensic Science Consultant, C&EN Media Group
%7Bc912bc96-7ed1-4688-b43a-dc2c45a676b3%7D_Banner
Labels (2)
Labels
Achieving the Pesticide MRLs with GC/MS/MS Using Hydrogen Carrier Gas
Thursday, April 20, 2023
Register
Recurring helium shortages and increased prices boost the demand for performing GC/MS analysis with alternative carrier gasses. While helium is the best carrier gas for GC/MS, hydrogen is the second-best alternative. However, unlike helium, hydrogen is not an inert gas. Hence, it can cause peak tailing, distorted ion ratios in the mass spectrum, poor library matching, and sensitivity loss.    Pesticides analysis can be challenging even with helium carrier gas given their diverse and labile nature. This presentation discusses the key strategies for analyzing pesticides with hydrogen carrier gas while delivering high-quality uncompromised results. To achieve the required detection limits with hydrogen carrier gas, the injection conditions were optimized. Further, the EI source optimized for use with hydrogen carrier gas allowed for preventing undesirable in-source reactions. Finally, method translation, and retention time locking techniques allowed the use of the MRM transitions and retention times from the database created with helium carrier gas.    Key Learning Objectives: Optimization of GC conditions essential when using hydrogen carrier gas  Appropriate MS hardware selection, including the EI source optimized for use with hydrogen carrier gas  Method translation technique for maintaining the same retention times as the original method with helium carrier gas or to scale the analysis speed with accurate retention time prediction  Who Should Attend: Laboratory Managers  Chromatographers  New Product Developers  Brought to you by:   Speakers: Anastasia Andrianova GC/MS Applications Scientist, Agilent Technologies Melissa O'Meara Forensic Science Consultant, C&EN Media Group
%7B139de288-b5fa-4337-963c-5b2a1d047f50%7D_GC_1200x630
Labels (2)
Labels
The Newest Alternative to Animal Testing Method for Skin Sensitization
Wednesday, April 26, 2023
Register
In recent years, there has been a growing movement to promote alternative methods to animal testing and the EU and a few other countries have even moved to ban the import and sale of cosmetics that have been tested on animals. The Amino acid Derivative Reactivity Assay (ADRA) Method developed by Fujifilm, is an innovative alternative test method for skin sensitization without the use of animals and it was adopted by the OECD in 2022 as a reliable test method.    In this webinar, we will present the technical background of the ADRA method, the use of reagent kits to perform ADRA testing, and our solutions for ADRA analysis that deliver both enhanced selectivity and high-speed testing. Register for this webinar and learn more about how the ADRA method will help you better test the safety of cosmetics and pharmaceuticals.    Key Learning Objectives: Outline of the OECD TG442C (ADRA: Amino acid Derivative Reactivity Assay)   Overview of ADRA kits and related products  How to conduct ADRA testing using HPLC  Who Should Attend: R&D and Manufacturer of Cosmetics  Companies considering Alternative Methods to Animal Testing  Industries interested in Alternative Methods to Animal Testing  Brought to you by:   Speakers: Toshihiko Kasahara, Ph.D. Safety Eval. Center, ESG Div., Senior Expert, Fujifilm Corporation Suguru Kitagawa International Sales, EU Region, Fujifilm Wako Pure Chemical Corporation Ayako Nomura Analytical Instr. Div., Application Specialist, Shimadzu Corporation Melissa O'Meara Forensic Science Consultant, C&EN Media Group
ACS Webinars Hub Placeholder Image.png
Labels (2)
Labels
Important In Vitro Inhibition Study Design & Analysis Concerns
Tuesday, May 2, 2023
Register
When evaluating drug-drug interaction (DDI) risk of an investigational drug, a battery of studies is needed to investigate victim/perpetrator potential. One of these comprises evaluation of the potential of a new therapy to inhibit drug-metabolizing enzymes, which can impact clearance of concomitantly administered drugs. The team at XenoTech has built a reputation of dedicating high-quality resources and specialists to conduct such studies with scientific rigor.    In this webinar, Jennifer Horkman, Study Director Team Supervisor in Metabolism Research at XenoTech, will address frequently asked questions from sponsors seeking inhibition studies and elaborate on some recommendations to achieve successful regulatory submission. Points of discussions will include an overview of enzyme inhibition studies and critical considerations in design, from determination of supporting data to conclusive interpretation.    The Q&A portion of this webinar will be led by Lois Haupt, Principal Scientist in Technical Advising at XenoTech. Both Jennifer and Lois have 20 years of DDI research experience at XenoTech and Lois’s 2015 paper on CYP inhibition is cited in the 2020 FDA final guidance, “In Vitro Drug Interaction Studies– Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions.”    Key Learning Objectives: Why is measuring CYP inhibition important? FDA guidance requirements CYP inhibition study design Standard study considerations CYP inhibition decision tree IC50 determinations Who Should Attend: Research scientists and drug development leadership aiming for successful IND / NDA submission, needing to meet regulatory requests and expectations, desiring to formulate a development plan that mitigates risks of late-stage failure, or simply wanting to better understand the ADME properties and potential DDI risks of their compound. Brought to you by:   Speakers: Jennifer Horkman Study Director, XenoTech Lois Haupt Principal Scientist, XenoTech Ann Thayer Contributing Editor, C&EN Media Group
%7Bb78086d6-f7a7-4c1d-9012-c755f4bba048%7D_drug-metabolizing-enzymes
Labels (2)
Labels
View:

From Food Chemistry to Career Advice to the latest on COVID-19 Vaccines, ACS Members with the Premium Package have exclusive access to the entire library of ACS Webinars® recordings.

Explore the Library

Stay up to date with the latest scientific research, applications and technology. Recordings of C&EN Webinars are available to the general public for 1 year after broadcast.

Explore the Library